MENU
+Compare
SRTS
Stock ticker: NASDAQ
AS OF
May 14, 04:59 PM (EDT)
Price
$4.81
Change
+$0.22 (+4.79%)
Capitalization
61.97M

SRTS Sensus Healthcare Forecast, Technical & Fundamental Analysis

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system... Show more

SRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SRTS with price predictions
May 13, 2025

SRTS's RSI Indicator recovers from oversold territory

The RSI Indicator for SRTS moved out of oversold territory on May 06, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 13, 2025. You may want to consider a long position or call options on SRTS as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on May 09, 2025. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

SRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SRTS entered a downward trend on May 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.269) is normal, around the industry mean (24.179). P/E Ratio (126.000) is within average values for comparable stocks, (79.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.520) is also within normal values, averaging (42.574).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SRTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
SRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SRTS is expected to report earnings to fall 46.67% to 4 cents per share on May 15

Sensus Healthcare SRTS Stock Earnings Reports
Q1'25
Est.
$0.05
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
Q2'24
Beat
by $0.08
Q1'24
Beat
by $0.17
The last earnings report on February 05 showed earnings per share of 9 cents, missing the estimate of 10 cents. With 49.21K shares outstanding, the current market capitalization sits at 61.97M.
A.I. Advisor
published General Information

General Information

a manufacturer of skin cancer treatment products

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
851 Broken Sound Parkway, NW
Phone
+1 561 922-5808
Employees
35
Web
https://www.sensushealthcare.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

SRTS and Stocks

Correlation & Price change

A.I.dvisor tells us that SRTS and CDNA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRTS and CDNA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRTS
1D Price
Change %
SRTS100%
+0.88%
CDNA - SRTS
32%
Poorly correlated
-1.41%
NTRA - SRTS
28%
Poorly correlated
-3.19%
MTD - SRTS
28%
Poorly correlated
+0.21%
RDNT - SRTS
27%
Poorly correlated
+6.14%
PLSE - SRTS
27%
Poorly correlated
+0.30%
More